This study looks at *Visudyne* (a medication known as verteporfin) to treat a type of recurring brain cancer called *glioblastoma*. Glioblastoma can have a change in a gene called *EGFR* (epidermal growth factor receptor), which can make the tumor grow faster. Visudyne is usually used with light for eye diseases but here, it will be used like chemotherapy to target tumor cells.

The study has two phases:

• Phase I: Tests the safety and best dose of Visudyne.
• Phase II: Checks if Visudyne stops or slows down the tumor and how long patients survive.

Participants will receive Visudyne through an IV once a week for several weeks. The study will check on patients after the treatment ends to see how they are doing.

• Participants must have a specific gene mutation and have had certain treatments before.
• They will need a special IV line called a port to receive the medication.
• They should not participate if pregnant, breastfeeding, or if they have severe health issues unrelated to their brain tumor.